Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Angiogenesis and Tumor Research

Executive Summary: Anlotinib hydrochloride (APExBIO, C8688) is a novel small-molecule inhibitor targeting VEGFR2, PDGFRβ, and FGFR1 with nanomolar potency, validated in both in vitro and in vivo preclinical models (Xie et al., 2018). It robustly inhibits endothelial cell migration and capillary tube formation with low cytotoxicity at functional concentrations. Oral bioavailability ranges from 28–77% depending on species, with high plasma protein binding and blood-brain barrier penetration (APExBIO). Safety studies indicate a high LD₅₀ and minimal systemic toxicity. Anlotinib outperforms sunitinib and other TKIs in comparative anti-angiogenic benchmarks (Prescission).

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is essential in tumor growth and metastasis. Tumor proliferation is dependent on angiogenic processes once mass exceeds ~1 mm³ (Xie et al., 2018). Vascular endothelial growth factor (VEGF) and its receptors (VEGFR1, VEGFR2, VEGFR3) mediate the majority of pro-angiogenic signaling in cancer. Among these, VEGFR2 is the principal driver of endothelial cell migration, proliferation, and capillary morphogenesis. Platelet-derived growth factor receptor β (PDGFRβ) and fibroblast growth factor receptor 1 (FGFR1) provide critical complementary signals for vascular stabilization and maturation. Multi-targeted tyrosine kinase inhibitors (TKIs) such as anlotinib enable simultaneous disruption of these convergent pathways, providing a rational approach to suppressing tumor angiogenesis and overcoming resistance mechanisms observed with single-target agents (Olodaterolmed).

Mechanism of Action of Anlotinib hydrochloride

Anlotinib hydrochloride selectively binds to the ATP-binding pockets of VEGFR2, PDGFRβ, and FGFR1 tyrosine kinases. This binding potently inhibits receptor autophosphorylation, blocking downstream ERK/MAPK pathway activation. In EA.hy 926 human vascular endothelial cells, anlotinib suppresses VEGF-, PDGF-BB-, and FGF-2-induced cell migration and capillary-like tube formation in a concentration-dependent manner. The IC₅₀ values are 5.6 ± 1.2 nM for VEGFR2, 8.7 ± 3.4 nM for PDGFRβ, and 11.7 ± 4.1 nM for FGFR1 under serum-free, growth-factor-stimulated conditions (Xie et al., 2018). At concentrations up to 1 μM, no significant cytotoxicity is observed, indicating a wide functional window for cell-based assays. By reducing phosphorylation of VEGFR2, PDGFRβ, and FGFR1, anlotinib disrupts angiogenic signaling, leading to reduced vascular density and inhibition of tumor growth (Dovitinib.com; extends with new IC₅₀ and toxicity data).

Evidence & Benchmarks

• Anlotinib inhibits VEGF-induced proliferation of HUVECs with picomolar IC₅₀ values (Xie et al., 2018).
• In EA.hy 926 cell migration assays, anlotinib produces complete inhibition at <100 nM concentrations under VEGF, PDGF-BB, or FGF-2 stimulation (APExBIO).
• Capillary tube formation is blocked in vitro at nanomolar concentrations, outperforming sunitinib, sorafenib, and nintedanib in matched conditions (Prescission).
• Oral bioavailability in rats (28%–58%) and dogs (41%–77%) is confirmed via single-dose pharmacokinetic studies. Plasma protein binding is 93%–97% (Xie et al., 2018).
• Terminal half-life is 5.1 ± 1.6 h (rats) and 22.8 ± 11.0 h (dogs), supporting daily dosing regimens (Xie et al., 2018).
• In vivo, anlotinib reduces tumor vascular density and induces tumor regression in mouse xenograft models (Xie et al., 2018).
• 14-day oral safety studies show LD₅₀ >1700 mg/kg with no significant liver, kidney, bone marrow, reproductive, or genotoxicity (APExBIO).
• Low risk for drug-drug interactions, with minor inhibition of CYP3A4 and CYP2C9 observed in vitro (Xie et al., 2018).
• Validated for capillary tube formation, migration, and signaling assays in anti-angiogenic research workflows (MAP Kinase Fragment; details protocol optimization scenario).

Applications, Limits & Misconceptions

Anlotinib hydrochloride is widely used in preclinical research for the study of angiogenesis, tumor biology, and tyrosine kinase signaling pathways. Its functional window allows for evaluation of anti-angiogenic activity without confounding cytotoxicity, making it suitable for endothelial cell migration and capillary tube formation assays. In cancer models, it is employed to dissect mechanisms of tumor vascularization and test anti-tumor efficacy of multi-targeted TKI strategies. However, direct cytotoxic effects on tumor cells are limited at sub-micromolar doses. The compound should be handled as a research-use-only reagent and not administered to humans or animals outside of experimental protocols (Anlotinib hydrochloride product page).

Common Pitfalls or Misconceptions

• Not a direct cytotoxin: Anlotinib hydrochloride does not directly kill tumor cells at nanomolar concentrations; anti-tumor effects are mediated via anti-angiogenesis.
• Assay selection: Cytotoxicity in endothelial cells is minimal up to 1 μM; observed effects in migration or tube formation are not due to cell death.
• Species differences: Pharmacokinetic parameters vary between species; clinical extrapolation requires caution.
• Not a pan-RTK inhibitor: Anlotinib is selective for VEGFR2, PDGFRβ, and FGFR1; other tyrosine kinases (e.g., EGFR, ALK) are not substantially inhibited at recommended doses.
• For research use only: The compound is not approved for therapeutic use in humans or veterinary medicine.

Workflow Integration & Parameters

Anlotinib hydrochloride (SKU C8688, APExBIO) is supplied as a hydrochloride salt and should be stored at -20°C in a desiccated environment. For capillary tube formation assays, working concentrations range from 1–100 nM in serum-free media, with incubation at 37°C and 5% CO₂ for 4–18 h. Migration assays (e.g., scratch or Boyden chamber) typically use 10–100 nM under growth factor stimulation. For signaling pathway analysis, cells are pretreated with anlotinib for 30–60 min prior to stimulation, followed by Western blot analysis of ERK phosphorylation. The compound is compatible with phenol red-free and low-serum conditions. Positive controls include sunitinib or sorafenib for benchmarking. Anlotinib is suitable for in vivo cancer models, with oral dosing regimens adjusted by species-specific pharmacokinetics and metabolic clearance rates (GTP Binding Protein 1 Fragment; extends with detailed dosing and storage recommendations).

Conclusion & Outlook

Anlotinib hydrochloride is a validated multi-target tyrosine kinase inhibitor offering high potency and selectivity against VEGFR2, PDGFRβ, and FGFR1. It is a preferred tool for anti-angiogenic research and preclinical tumor biology, with robust safety and workflow compatibility. Ongoing studies are further elucidating its translational impact in cancer therapy and angiogenesis inhibition. For detailed protocols and ordering, researchers are referred to the APExBIO official product page.